45.60
price up icon1.81%   0.81
after-market アフターアワーズ: 45.54 -0.06 -0.13%
loading
前日終値:
$44.79
開ける:
$45.21
24時間の取引高:
3.57M
Relative Volume:
1.12
時価総額:
$12.44B
収益:
$2.17B
当期純損益:
$521.27M
株価収益率:
25.76
EPS:
1.77
ネットキャッシュフロー:
$633.79M
1週間 パフォーマンス:
+2.54%
1か月 パフォーマンス:
+4.76%
6か月 パフォーマンス:
+40.83%
1年 パフォーマンス:
+98.61%
1日の値動き範囲:
Value
$44.83
$45.72
1週間の範囲:
Value
$43.86
$45.75
52週間の値動き範囲:
Value
$22.80
$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name
名前
Exelixis Inc
Name
セクター
Healthcare (1164)
Name
電話
(650) 837-7000
Name
住所
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
職員
1,147
Name
Twitter
@exelixisinc
Name
次回の収益日
2025-07-28
Name
最新のSEC提出書
Name
EXEL's Discussions on Twitter

EXEL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EXEL
Exelixis Inc
45.60 12.21B 2.17B 521.27M 633.79M 1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-08 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-06-24 アップグレード Stephens Equal-Weight → Overweight
2025-02-24 ダウングレード Wells Fargo Overweight → Equal Weight
2025-01-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-01-24 ダウングレード Oppenheimer Outperform → Perform
2024-12-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-12-17 ダウングレード BofA Securities Buy → Neutral
2024-10-16 繰り返されました RBC Capital Mkts Outperform
2024-09-19 開始されました UBS Neutral
2024-04-11 ダウングレード Barclays Overweight → Equal Weight
2023-12-19 開始されました BTIG Research Buy
2023-12-15 開始されました Citigroup Buy
2023-09-26 開始されました H.C. Wainwright Buy
2023-08-22 繰り返されました Oppenheimer Outperform
2023-08-08 開始されました SVB Securities Market Perform
2023-07-11 再開されました Morgan Stanley Equal-Weight
2023-05-10 再開されました Piper Sandler Overweight
2023-03-09 開始されました Wells Fargo Overweight
2023-01-26 開始されました Credit Suisse Outperform
2022-10-18 開始されました JMP Securities Mkt Outperform
2022-06-24 開始されました BMO Capital Markets Outperform
2021-11-19 開始されました Piper Sandler Overweight
2021-11-03 再開されました Jefferies Buy
2021-10-07 開始されました Jefferies Buy
2021-08-06 繰り返されました H.C. Wainwright Buy
2021-06-15 開始されました H.C. Wainwright Buy
2021-05-18 再開されました Goldman Sell
2021-03-31 開始されました Credit Suisse Outperform
2021-03-12 開始されました Wolfe Research Outperform
2020-03-04 開始されました Barclays Overweight
2020-01-13 開始されました SunTrust Buy
2019-11-13 開始されました BofA/Merrill Buy
2019-03-18 アップグレード Morgan Stanley Underweight → Equal-Weight
2018-09-17 開始されました Goldman Neutral
2018-09-10 開始されました Morgan Stanley Underweight
2018-05-11 繰り返されました Needham Buy
2017-10-17 繰り返されました Needham Buy
2017-10-17 繰り返されました RBC Capital Mkts Outperform
2017-10-16 繰り返されました SunTrust Buy
2017-09-22 ダウングレード Leerink Partners Outperform → Mkt Perform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-09-12 繰り返されました Needham Buy
2017-07-14 開始されました SunTrust Buy
2017-03-31 開始されました Needham Buy
2017-03-16 開始されました Oppenheimer Perform
2017-02-28 ダウングレード Stifel Buy → Hold
2016-11-03 開始されました Deutsche Bank Buy
2016-10-10 アップグレード Piper Jaffray Neutral → Overweight
2016-09-15 繰り返されました Stifel Buy
すべてを表示

Exelixis Inc (EXEL) 最新ニュース

pulisher
Jul 24, 2025

EU approves cabozantinib for previously treated neuroendocrine tumors By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Exelixis and Ipsen's Breakthrough Approval of CABOMETYX in Neuroendocrine Tumors: A Game Changer in a High-Growth Oncology Niche - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire

Jul 24, 2025
pulisher
Jul 24, 2025

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Ipsen wins EU nod for Exelixis cancer drug (EXEL:NASDAQ) - Seeking Alpha

Jul 24, 2025
pulisher
Jul 24, 2025

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors - GlobeNewswire Inc.

Jul 24, 2025
pulisher
Jul 24, 2025

Citizens JMP Maintains Buy Rating on Exelixis with $50 Price Target - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Exelixis stock poised for Q2 beat on strong script growth, JMP says - Investing.com Canada

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Exelixis Inc. stockExceptional growth trajectory - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Exelixis Advances Cancer Studies with Rising Analyst Confidence - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Earnings Preview: Exelixis to Report Financial Results Post-market on July 28 - 富途牛牛

Jul 22, 2025
pulisher
Jul 22, 2025

Exelixis Inc. Stock Analysis and ForecastLightning-fast growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Morgan Stanley Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛

Jul 22, 2025
pulisher
Jul 21, 2025

Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 30.6% Revenue Growth and Future Prospects - DirectorsTalk Interviews

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Exelixis Inc. stock priceHigh-performance investment picks - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com

Jul 18, 2025
pulisher
Jul 16, 2025

Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st

Jul 16, 2025
pulisher
Jul 15, 2025

Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 15, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace

Jul 14, 2025
pulisher
Jul 14, 2025

Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com

Jul 14, 2025
pulisher
Jul 14, 2025

Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma? - TipRanks

Jul 14, 2025
pulisher
Jul 12, 2025

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail

Jul 12, 2025
pulisher
Jul 11, 2025

Barclays Remains a Hold on Exelixis (EXEL) - The Globe and Mail

Jul 11, 2025
pulisher
Jul 10, 2025

Assessing Exelixis: Insights From 12 Financial Analysts - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Exelixis cut to sector perform at RBC as cash flows fairly valued - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Jul 10, 2025

Exelixis Inc (EXEL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Exelixis Inc (EXEL) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
WYSZOMIERSKI JACK L
Director
Jun 03 '25
Sale
43.09
7,535
324,683
358,882
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):